This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Assays & screens			
<i>In vitro</i> tumor cell-specific bioluminescence imaging (CS-BLI) assay	<p>The CS-BLI assay could improve the quality of drug screening hits by allowing high throughput screening in tumor/stromal cell cocultures. In multiple human cancer cell lines, the assay showed that cancer cells can become resistant to standard chemotherapy when stromal cells are present. A CS-BLI-based high throughput screen showed that reversine had greater activity against human multiple myeloma (MM) cells in the presence of stromal cells than in their absence. Next steps include expanding the assay to other tumor cell types. Reversine is a research chemical used to dedifferentiate cells.</p> <p>SciBX 3(12); doi:10.1038/scibx.2010.388 Published online March 25, 2010</p>	Patent application filed; licensing status undisclosed	<p>McMillin, D.W. <i>et al. Nat. Med.</i>; published online March 14, 2010; doi:10.1038/nm.2112</p> <p>Contact: Constantine S. Mitsiades, Dana-Farber Cancer Institute, Boston, Mass. e-mail: constantine_mitsiades@dfci.harvard.edu</p>